

June 2020



Corporate News

- In light of COVID-19, Samumed has transitioned to remote work for all non-essential employees; our clinical and preclinical activities continue as planned
- Dr. Michael White has joined us as our Chief Scientific Officer (click [here](#) for bio)



Osteoarthritis (OA)

- We initiated an additional pivotal Phase 3 study for lorecivint
- We published a peer-reviewed article in *Arthritis and Rheumatology* containing complete results from our first Phase 2 study for lorecivint (click [here](#))